Molecular Classification of Endometrial Cancer: Impact on Adjuvant Treatment Planning.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06584630

Enrollment

Registered

2024-09-05

Start date

2022-01-01

Completion date

2025-12-31

Last updated

2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial Cancer

Brief summary

Molecular classification that has been recently incorporated in FIGO classification of endometrial cancer is a new triage tool for the better management of endometrial cancer patients.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Histological confirmation of endometrial cancer. * Surgical treatment at our Gynecological - Oncology Unit.

Exclusion criteria

* Refusal to be tested for the molecular classification * Presence of a synchronous neoplasm.

Design outcomes

Primary

Measure	Time frame	Description
Multidisciplinary Team Board decision change	2 years (study completion)	MDT decision for adjuvant treatment (Rate of adjuvant treatment change)

Countries

Greece

Outcome results